On this page
Fluocinonide
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Fluocinonide | .5 mg/mL | 310364 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 209699-001 | FLUOCINONIDE | SOLUTION | FLUOCINONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | November 29, 2018 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260320). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Fluocinonide Topical Solution USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Fluocinonide Topical Solution USP, 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis Maceration of the skin Secondary infection Skin atrophy Striae Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Quagen Pharmaceuticals LLC. at 1-888-344-9603 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions.
Description
openFDA Drug LabelingDESCRIPTION Fluocinonide topical solution USP, 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4 -diene-3,20 -dione,21-(acetyloxy)-6 ,9 -difluoro -11-hydro xy-16 ,17-[(1- methylethylidene)bis(oxy)]-,(6 α, 11β, 16 α)-. It has the following chemical structure: Fluocinonide, USP is white or almost white microcrystalline powder. It is practically insoluble in water, very slightly soluble in ether, slightly soluble in ethanol, methanol and dioxane, sparingly soluble in acetone and chloroform. Fluocinonide topical solution USP, 0.05% contains fluocinonide USP, 0.5 mg/mL in a solution of citric acid monohydrate, dehydrated alcohol (35%), diisopropyl adipate, propylene glycol and purified water. In this formulation, the active ingredient is totally in solution. Fluocinonide topical solution USP, 0.5%
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS .) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-886-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Fluocinonide Topical Solution USP, 0.05% is clear solution free from particulate matter and is supplied as: NDC 70710-1284-8 in bottle of 20 mL NDC 70710-1284-3 in bottle of 60 mL Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat, above 40°C (104°F). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please address medical inquiries to, (MedicalAffairs@zydususa.com) Tel.: 1-877-993-8779.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLUOCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-9583-1 | 63629-9583 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (63629-9583-1) / 60 mL in 1 BOTTLE | December 12, 2022 |
| 72162-1270-6 | 72162-1270 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-1270-6) / 60 mL in 1 BOTTLE | April 19, 2019 |
| 72162-2146-6 | 72162-2146 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-2146-6) / 60 mL in 1 BOTTLE | February 27, 1995 |
| 72162-2490-2 | 72162-2490 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-2490-2) / 20 mL in 1 BOTTLE | May 14, 2025 |
| 72162-2490-6 | 72162-2490 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-2490-6) / 60 mL in 1 BOTTLE | May 14, 2025 |
| 0168-0134-60 | 0168-0134 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 1 BOTTLE in 1 CARTON (0168-0134-60) / 60 mL in 1 BOTTLE | February 27, 1995 |
| 21922-001-01 | 21922-001 | Encube Ethicals, Inc. | 1 BOTTLE in 1 CARTON (21922-001-01) / 60 mL in 1 BOTTLE | April 19, 2019 |
| 43386-026-02 | 43386-026 | Lupin Pharmaceuticals,Inc. | 1 BOTTLE in 1 CARTON (43386-026-02) / 20 mL in 1 BOTTLE | July 21, 2017 |
| 43386-026-06 | 43386-026 | Lupin Pharmaceuticals,Inc. | 1 BOTTLE in 1 CARTON (43386-026-06) / 60 mL in 1 BOTTLE | July 21, 2017 |
| 33342-320-84 | 33342-320 | Macleods Pharmaceuticals Limited | 1 BOTTLE in 1 CARTON (33342-320-84) / 20 mL in 1 BOTTLE | April 24, 2018 |
| 33342-320-85 | 33342-320 | Macleods Pharmaceuticals Limited | 1 BOTTLE in 1 CARTON (33342-320-85) / 60 mL in 1 BOTTLE | April 24, 2018 |
| 72603-703-01 | 72603-703 | NorthStar RxLLC | 1 BOTTLE in 1 CARTON (72603-703-01) / 60 mL in 1 BOTTLE | July 1, 2025 |
| 40032-026-06 | 40032-026 | Novel Laboratories, Inc. | 1 BOTTLE in 1 CARTON (40032-026-06) / 60 mL in 1 BOTTLE | July 21, 2017 |
| 68071-3918-6 | 68071-3918 | NuCare Pharmaceuticals, Inc. | 1 BOTTLE in 1 CARTON (68071-3918-6) / 60 mL in 1 BOTTLE | November 26, 2025 |
| 70752-154-05 | 70752-154 | QUAGEN PHARMACEUTICALS LLC | 1 BOTTLE in 1 CARTON (70752-154-05) / 60 mL in 1 BOTTLE | March 15, 2025 |
| 71656-094-20 | 71656-094 | Saptalis Pharmaceuticals, LLC. | 20 mL in 1 BOTTLE (71656-094-20) | May 11, 2026 |
| 71656-094-60 | 71656-094 | Saptalis Pharmaceuticals, LLC. | 60 mL in 1 BOTTLE (71656-094-60) | May 11, 2026 |
| 51672-1273-2 | 51672-1273 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (51672-1273-2) / 20 mL in 1 BOTTLE, PLASTIC | December 31, 1996 |
| 51672-1273-4 | 51672-1273 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (51672-1273-4) / 60 mL in 1 BOTTLE, PLASTIC | December 31, 1996 |
| 70771-1375-3 | 70771-1375 | Zydus Lifesciences Limited | 60 mL in 1 BOTTLE (70771-1375-3) | November 1, 2018 |
| 70771-1375-8 | 70771-1375 | Zydus Lifesciences Limited | 20 mL in 1 BOTTLE (70771-1375-8) | November 1, 2018 |
| 70710-1284-3 | 70710-1284 | Zydus Pharmaceuticals USA Inc. | 60 mL in 1 BOTTLE (70710-1284-3) | November 1, 2018 |
| 70710-1284-8 | 70710-1284 | Zydus Pharmaceuticals USA Inc. | 20 mL in 1 BOTTLE (70710-1284-8) | November 1, 2018 |
| 63629-9583 | 63629-9583 | Bryant Ranch Prepack | — | April 19, 2019 |
| 72162-1270 | 72162-1270 | Bryant Ranch Prepack | — | April 19, 2019 |
| 72162-2146 | 72162-2146 | Bryant Ranch Prepack | — | February 27, 1995 |
| 72162-2490 | 72162-2490 | Bryant Ranch Prepack | — | May 14, 2025 |
| 0168-0134 | 0168-0134 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | February 27, 1995 |
| 21922-001 | 21922-001 | Encube Ethicals, Inc. | — | April 19, 2019 |
| 43386-026 | 43386-026 | Lupin Pharmaceuticals,Inc. | — | July 21, 2017 |
| 33342-320 | 33342-320 | Macleods Pharmaceuticals Limited | — | April 24, 2018 |
| 72603-703 | 72603-703 | NorthStar RxLLC | — | July 1, 2025 |
| 40032-026 | 40032-026 | Novel Laboratories, Inc. | — | July 21, 2017 |
| 68071-3918 | 68071-3918 | NuCare Pharmaceuticals, Inc. | — | April 19, 2019 |
| 70752-154 | 70752-154 | QUAGEN PHARMACEUTICALS LLC | — | March 15, 2025 |
| 71656-094 | 71656-094 | Saptalis Pharmaceuticals, LLC. | — | May 11, 2026 |
| 51672-1273 | 51672-1273 | Sun Pharmaceutical Industries, Inc. | — | December 31, 1996 |
| 70771-1375 | 70771-1375 | Zydus Lifesciences Limited | — | November 1, 2018 |
| 70710-1284 | 70710-1284 | Zydus Pharmaceuticals USA Inc. | — | November 1, 2018 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.